What Is Drawing Attention To Viatris (VTRS)?

Simply Wall St · 1d ago

Viatris (VTRS) just put a complicated third quarter on the table. The healthcare group reported a wider quarterly net loss and trimmed revenue for the period, yet lifted full year earnings and sales guidance.

The guidance upgrade and steady dividend have arrived alongside a strong rerating in Viatris. The 30 day share price return of 19.38% and 90 day share price gain of 28.28% contribute to a 67.09% year to date move, while the 1 year total shareholder return of 101.10% and 3 year total shareholder return of 149.91% indicate that momentum has been building over a longer period.

Scan how other potential turnaround stories compare to Viatris by reviewing the hand picked 32 high quality undervalued stocks that pair balance sheet strength with cash generation.

After a 67% year to date climb, Viatris now trades only a few percent below the average analyst target, while some intrinsic value models imply a far wider gap. Which reference point looks closer to fair value?

Most Popular Narrative: 4.1% Overvalued

On Simply Wall St, the analyst consensus Narrative sets a fair value of $20.00 for Viatris, a touch below the recent $20.82 close, and anchors that view on how the product mix and cost program reshape the business.

The main factor identified is continued execution on cost savings, portfolio reshaping and the build-out of non-opioid pain and complex generics, so that earnings quality keeps improving even as lower-margin oral generics and some emerging markets face pressure.

See why 50 investors see Viatris as 4% overvalued.

Result: Fair Value of $20.00 (OVERVALUED)

Still, Viatris faces two clear pressure points: ongoing price erosion on mature drugs and unresolved manufacturing remediation that could both weigh on margins and cash generation.

Find out about the key risks to this Viatris narrative.

Another View: Viatris Through The P/S Lens

Our DCF model points one way, but the simple P/S yardstick paints a very different picture for Viatris. The stock trades at about 1.6x sales, while peers in the US pharmaceuticals group sit nearer 4.1x and the fair ratio is 4.6x. That gap could signal mispricing, or it could reflect real concerns about profitability and execution. Which explanation do you find more convincing?

For a closer look at how the numbers stack up, including how that sales multiple compares across peers and against the fair ratio the market could move toward, See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:VTRS P/S Ratio as at Nov 2026
NasdaqGS:VTRS P/S Ratio as at Nov 2026

Next Steps

The Viatris story has presented mixed messages so far. If you want to move quickly and firm up your own stance, start by weighing the 3 key rewards and 1 important warning sign

Looking for more Viatris style investment ideas?

If you want to keep sharpening your watchlist, use the Simply Wall St screener to surface clear opportunities instead of relying on headlines and hunches.